U.S. markets close in 22 minutes
  • S&P 500

    3,632.89
    +3.24 (+0.09%)
     
  • Dow 30

    29,854.52
    -17.95 (-0.06%)
     
  • Nasdaq

    12,190.75
    +96.34 (+0.80%)
     
  • Russell 2000

    1,851.64
    +6.62 (+0.36%)
     
  • Crude Oil

    45.51
    -0.20 (-0.44%)
     
  • Gold

    1,788.20
    -23.00 (-1.27%)
     
  • Silver

    22.63
    -0.82 (-3.48%)
     
  • EUR/USD

    1.1956
    +0.0043 (+0.36%)
     
  • 10-Yr Bond

    0.8470
    -0.0310 (-3.53%)
     
  • GBP/USD

    1.3306
    -0.0050 (-0.38%)
     
  • USD/JPY

    104.0550
    -0.1950 (-0.19%)
     
  • BTC-USD

    16,775.52
    -391.13 (-2.28%)
     
  • CMC Crypto 200

    328.24
    -9.26 (-2.74%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

Inspire Medical Systems, Inc. to Report Third Quarter 2020 Financial Results on November 2, 2020

Inspire Medical Systems, Inc.
·1 min read

MINNEAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the third quarter 2020 after the close of trading on Monday, November 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Monday, November 2rd @ 5:00 p.m. Eastern Time:

Domestic:

877-407-0792

International:

201-689-8263

Conference ID:

13710653

Webcast:

http://public.viavid.com/index.php?id=141564

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989